Apex Biotechnology Corp. · TWSE:1733
Apex Biotechnology — 2026 Investor Conference
13 slides from Apex Biotechnology's conference presentation, Jun 11, 2026
Slide 1: 2026 June
2026 June
Slide 2: Disclaimer
Disclaimer • The information provided in this presentation, including views on future operations and development, is based on information currently available to the Company and reasonable expectations. Such information may contain forward-looking statements. • Actual results of operations may differ
Slide 3: Company profile
Company profile • TSEC 1733 • Industry IVD Medical Device • Operation Locations .Head quarter: No. 7, Li-Hsin 5th Rd., Hsinchu Science Park, Hsinchu, Taiwan .Tao Yuan Factory: No. 180, Lane 70, Wuqing Rd., Dayuan Dist., Taoyuan City, Taiwan .Suzhou Corp.: Room 106, No.2, Kecheng Road, SIP, Suzhou, C
Slide 4: Milestone
Milestone 1997-2001 2002-2006 2007-2011 1997 ApexBio set-up 2002 ISO9001/13485 Notified 2009 Taoyuan factory set-up 1998 BGM FDA 510K approval 2003 CE IVDD notified 2011 AEO certified by Customs Admin 2001 Transit IPO listed to TSEC 2004 Taiwan GMP notified 2011 3rd time FDA on-site inspection 2001
Slide 5: Quality System
Quality System Region The Authority Regulatory compliance Taiwan TFDA QMS ISO 13485:2016 EU CE CE mark number:CE0197 EN ISO 15197:2015 Quality System Regulation (21 CFR Part 820) USA FDA 510K’s on-site audit w/o 483 citations 2023 MDSAP (USA/Canada/Brazil) China NMPA Medical Device Class II 2017 pas
Slide 6: Product specification please refer to company website
Product specification please refer to company website
Slide 7: GCTU link Hemoglobin Glucose link
GCTU link Hemoglobin Glucose link Uric Acid link G/K POC wifi Ketone link Glucose POC link Glucose link
Slide 8: New pipeline product
New pipeline product ◼ Rapid test TFDA QMS passed • COVID-19 Antigen Rapid Test Kit • KP Rapid Test Kit • Influenza Rapid Test Kit Developing items: • Vector-borne Disease Detection for Mosquito-borne Illnesses • Economic Animal and Animal Epidemic Prevention Detection • DOA ◼ Home use CGM
Slide 9: Global sales distribution
Global sales distribution Territory 2024 2025 2026/1Q America 39% 46% 39% EU 48% 44% 53% Asia 12% 9% 8% Africa 1% 1% 0
Slide 10: Finance Performance
Finance Performance 2024 2025 2026/1Q Revenue 1,852,211 1,944,907 519,723 Gross margin 521,342 538,741 175,664 Operation profit 128,464 140,726 87,211 Profit after tax 128,104 163,038 81,370 EPS 1.28 1.63 0.81 G/M ratio 28% 28% 34% Shipped Meter Qty (kit) 1,368K 1,258K 281K Shipped Strip Qty (pcs) 8
Slide 11: Product ratio
Product ratio 2025 2026/1Q BGM & A1C Electrode BGM & A1C Electrode Non-BGM 其他(附件) Non-BGM Others 5% 5% 12% 20% 2% 2% 73% 81% Non-BGM Hemoglobin/Ketone/Uric Acid/Lactate/Cholesterol/ Pesticide quick check etc.
Slide 12: 12th Corporate Governance Evaluation (2025)
the 12th Corporate Governance Evaluation (2025年) Points for Number of AA/A+ Total number Distribution Scoring Category satisfied inapplicable Extra Credit of indicators weight formula indicators indicators Indicators Year 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 Protecting Shareholder Right
Slide 13: Thank you
Thank you